VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX
Delisted
VIRX was delisted on the 3rd of February, 2025.
63 hedge funds and large institutions have $44.2M invested in Viracta Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 24 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
29% less capital invested
Capital invested by funds: $62.4M → $44.2M (-$18.2M)
63% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 24
Holders
63
Holding in Top 10
1
Calls
$716K
Puts
$226K
Top Buyers
| 1 | +$1.99M | |
| 2 | +$901K | |
| 3 | +$761K | |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$616K |
| 5 |
E
Ergoteles
New York
|
+$443K |
Top Sellers
| 1 | -$5.04M | |
| 2 | -$1.51M | |
| 3 | -$792K | |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$698K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$475K |